Glaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
Glaukos Announces Participation in Upcoming Investor Conferences
Glaukos Announces First Quarter 2024 Financial Results
Glaukos Announces the Release of its 2023 Sustainability Report
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results